Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Immunotherapy related patient-reported outcomes from five randomized controlled trials in patients with triple negative breast cancer: A systematic review.

View Full Paper
Ask AI
Bookmark
Share

Authors

CSCarrie ShaMLMarie LiuJGJohanna Goldberg

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sha et al. (2024) studied this question.

synapsesocial.com/papers/68e66f03b6db6435875fa1bchttps://doi.org/10.1200/jco.2024.42.16_suppl.e23167
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PO5-06-08: Real-world analysis of efficacy, adverse events and predictive biomarkers for advanced triple negative breast cancer (TNBC) treated with immune check point Inhibitors (ICI): A single center experience2024 · 1 citations
  2. 2PD-L1-Guided Chemo-Immunotherapy in Advanced Triple-Negative Breast Cancer: A Meta-Analysis of Survival Benefits and Toxicity Profiles2026 · 1 citations
  3. 3Efficacy of immunotherapy in older patients with triple-negative breast cancer: a systematic review2025
  4. 4Abstract PO2-03-10: Association of pathologic complete response with the 27-gene IO score and week 3 IOpath response following neoadjuvant pembrolizumab +/- intralymphatic cytokines in the neoIRX trial2024
  5. 5Association of immunotherapy infusion timing with outcomes in early-stage triple-negative breast cancer.2026